Abstract library

2 results for "sulfatinib".
#1697 An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967)
Introduction: Patients (pts) with advanced neuroendocrine tumors (NETs) who have failed sunitinib or everolimus have limited treatment options. Sulfatinib, a novel kinase inhibitor targeting tumor angiogenesis and immune evasion, has shown encouraging anti-tumor activity in patients with advanced NETs in a phase I study.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Jian Ming Xu
Authors: Xu J, Li J, Bai C M, Xu N, ...
Keywords: sulfatinib, net, orr, pfs
#1441 Epidemiology and Treatment Strategy of Neuroendocrine Neoplasms in North China
Introduction: Few studies had focus on the epidemiology of neuroendocrine neoplasms (NENs) , a rare disease, in China.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Qian-Nan Wang
Authors: Wang Q N, Jia R, Chen Y, Zhao C H, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.